Aemetis, Inc (NASDAQ:AMTX) Short Interest Update

Key Points

• Aemetis saw a notable decline in short interest in March — shorts fell 15.3% to 4,691,245 shares as of March 13, representing about 8.4% of shares outstanding and a days‑to‑cover of 3.6.
• In the latest quarter Aemetis reported EPS of -$0.24 (beating estimates) but revenue of $43.31M missed expectations of $72.07M, and analysts forecast full‑year EPS of roughly -2.07.
• Analyst views are mixed: Wall Street Zen upgraded AMTX to a "hold" while Weiss maintained a "sell," leaving a consensus rating of Hold and an average price target of $8.25; the stock trades near $3.25 with a market cap around $216.6M.

Aemetis, Inc (NASDAQ:AMTX - Get Free Report) was the recipient of a significant drop in short interest during the month of March. As of March 13th, there was short interest totaling 4,691,245 shares, a drop of 15.3% from the February 26th total of 5,537,109 shares. Based on an average daily trading volume, of 1,305,036 shares, the days-to-cover ratio is currently 3.6 days. Currently, 8.4% of the shares of the company are short sold.

Analyst Ratings Changes

Several research firms have commented on AMTX. Wall Street Zen raised Aemetis from a "sell" rating to a "hold" rating in a research note on Sunday, March 22nd. Weiss Ratings reiterated a "sell (e+)" rating on shares of Aemetis in a research note on Wednesday, January 21st. Finally, Loop Capital set a $1.75 target price on Aemetis in a report on Thursday, March 12th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $8.25.

Aemetis Stock Performance

AMTX stock opened at $3.25 on Tuesday. The stock has a market capitalization of $216.55 million, a PE ratio of -2.44 and a beta of 2.61. The company has a fifty day moving average of $1.84 and a 200-day moving average of $1.93. Aemetis has a one year low of $1.22 and a one year high of $3.66.

Aemetis (NASDAQ:AMTX - Get Free Report) last issued its quarterly earnings results on Thursday, March 12th. The specialty chemicals company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.04. The firm had revenue of $43.31 million for the quarter, compared to analyst estimates of $72.07 million. Equities analysts forecast that Aemetis will post -2.07 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aemetis

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. J. Derek Lewis & Associates Inc. acquired a new stake in shares of Aemetis in the 4th quarter valued at approximately $322,000. Caitong International Asset Management Co. Ltd acquired a new position in Aemetis during the fourth quarter worth $115,000. Virtu Financial LLC acquired a new position in Aemetis during the fourth quarter worth $31,000. XTX Topco Ltd purchased a new position in Aemetis in the fourth quarter worth $52,000. Finally, Quadrature Capital Ltd purchased a new position in Aemetis in the fourth quarter worth $77,000. Institutional investors and hedge funds own 27.02% of the company's stock.

Aemetis Company Profile

Aemetis, Inc, headquartered in Cupertino, California, is a renewable fuels and renewable natural gas producer dedicated to decarbonizing the transportation sector. The company operates two primary business segments: Aemetis Advanced Fuels, which manufactures ethanol, biodiesel and sustainable aviation fuel using patented carbon capture and separation technology; and Aemetis RNG, which develops dairy-based renewable natural gas projects in California for pipeline injection and transportation use.

Since its incorporation in 2006, Aemetis has expanded its production footprint through organic growth and strategic acquisitions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.